Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial

of the final appraisal document. 5.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has non-valvular atrial fibrillation and the healthcare professional responsible for their care thinks that apixaban is the right treatment, it should be available for use, in line with NICE's recommendations. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275) 6 Recommendations for further research 6.1 During this appraisal it was noted that there is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.
